Metformin Bp Bristol Laboratories (Metformin Hydrochloride)

Metformin acts primarily by inhibiting mitochondrial respiratory chain complex I, which reduces hepatic gluconeogenesis. It also activates AMP‑activated protein kinase (AMPK), enhancing glucose uptake in muscle and adipose tissue and increasing overall insulin sensitivity.

The dose of Metformin Bp Bristol Laboratories is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Metformin’s safety in pregnancy and lactation is not fully established. It may be used when the potential benefit outweighs the risk, but clinicians typically prefer alternative therapies. Breastfeeding mothers should consult their physician before continuing treatment.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Metformin belongs to the biguanide class and is often first‑line therapy because of its efficacy, low risk of hypoglycaemia, and favourable impact on weight. Compared with sulfonylureas, it does not cause insulin release, and unlike insulin, it is administered orally.

Store Metformin tablets at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, and avoid exposure to direct sunlight to maintain potency.

Metformin Bp Bristol Laboratories is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, excessive alcohol intake, or acute medical illnesses. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metformin is contraindicated in patients with known hypersensitivity to the drug, severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in those receiving iodinated contrast media without appropriate renal monitoring.